TGTX

TG Therapeutics Inc. (TGTX) | Rumor.io

TG Therapeutics

TGTX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#356

Bullish sentiment (50-day avg)88%

Price to earnings ratio20.7

Market capitalization8.6B

Earnings per share2.74

Dividend yield (TTM)—

Revenue (annual)616.3M

Net income (annual)447.2M

Social

What share of all stock conversation is about TGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% -0.01	0.01% 0	0.01% -0.04

Sep 29

$TGTX's subcutaneous formulation is expected to have a positive impact on its total addressable market, potentially increasing its valuation to $18-$22B.
Mike, the company's largest shareholder, has not sold any of his 14M+ shares, suggesting he believes in the company's potential for triple-digit growth.
A potential announcement, possibly related to updated guidance, trial updates, or other news, could lead to a significant price increase of 15-25% or more in a short period.

Generated by AI

Sentiment

Of the messages about TGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.78% -2.22	91.63% -0.33	90.6% +4.02	84.93% -3.41
Bearish	2.22% new	8.37% +0.33	9.4% -4.02	15.07% +3.41

Bullish· Sep 24

$TGTX has shown resilience in the face of market fluctuations, with a strong rebound after a 4% drop and a 85% YTD gain.
The company's profitable commercial status and strides in the multi-deca billion MS market make it an attractive investment opportunity, with the potential for a violent uptick in the next 3 months.
With the potential for dual-delivery model (both at-home injection and in-clinic infusion) and a subcutaneous Phase 3 readout in late 2026-early 2027, TGTX is well-positioned for future growth and success.

Bearish· Aug 3

$TGTX's EPS miss was due to inventory build for the SubQ launch, but this may be a capitalization error, and the company's long-term story is intact.
The stock's weakness after earnings was likely due to the EPS miss, which may have been justified by the company's own accounting practices.
$TGTX's consistent EPS misses have been a concern for Wall Street, and the stock's price action has been bearish, with some traders describing it as "absolute BS" and "very bear flaggish intraday".

Generated by AI

Topics

Of the messages about TGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	1.62%	13.71%
Announcements	100%	25%	32.19%	37.93%
Technical Analysis	0%	75%	65.79%	23.83%
Earnings	0%	0%	0%	20.87%
Controversies	0%	0%	0.4%	1.06%
Macro	0%	0%	0%	2.6%

Earnings· Aug 3

TG Therapeutics, Inc. (TGTX) reported Q2 2026 earnings with a GAAP EPS of $0.05, missing the FactSet consensus of $0.31 by $0.26.
The company beat revenue expectations with a 70.27% YoY increase to $240.34M, and raised its full-year 2026 total global revenue target to approximately $950M.
TGTX's Q2 2026 revenue growth was driven by a 64% YoY increase in BRIUMVI U.S. net product revenue to $228M, prompting the company to raise its guidance for the year.

Analysts· Aug 2

Analysts at Goldman Sachs upgraded TG Therapeutics to Neutral from Sell, with a price target of $12.
Analyst Mayank Mamtani at B.Riley Financial reiterated a Buy rating on TG Therapeutics with a price target of $32.
Analysts at HC Wainwright increased the price target for TG Therapeutics to $41.

Announcements· Mar 19

TG Therapeutics, Inc. has secured an additional $500 million in non-dilutive capital from Blue Owl Capital, expanding its share repurchase program to $300 million.
The new five-year, $750 million senior secured credit facility with Blue Owl Capital will provide financial flexibility to support opportunistic share repurchases and business development.
The company will repay its outstanding $250 million senior secured credit facility, resulting in a net raise of $500 million in non-dilutive capital, with the option to expand the facility by an additional $250 million.

Controversies· Aug 4

TG Therapeutics, Inc. (TGTX) is being investigated for securities fraud allegations by law firms Levi & Korsinsky and Berger Montague, with a lead plaintiff deadline of September 16, 2022.
A lawsuit has been filed against TG Therapeutics, alleging that the company made false and misleading statements regarding clinical trial data for its medications Ublituximab and Umbralisib.
The FDA's approval of TG's applications for these medications is unlikely due to concerns over the safety of the medications, according to the lawsuit.

Technical Analysis· Jun 10

$TGTX has formed a clean bullish engulfing flag, following a premarket long setup at $43.60.
The stock is exhibiting a textbook breakout, likely in response to new data that impressed investors.
$TGTX is showing a classic breakout pattern, indicating a potential increase in price.

Generated by AI

Community

Of the messages about TGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.18%	92.81%	90.28%
Newcomers	0%	2.82%	7.19%	9.72%

Regulars· Sep 29

The price of TGTX has been stuck at $55 for the last 3 months, but some regulars believe it will break out of this range and see significant gains, with one person thinking the subq window opening in November will lead to a price increase by Christmas.
Some regulars are optimistic about TGTX's future, citing its cash flow positivity and improving margins, with one person believing the company is worth north of $100 per share and that the longer the price stays stuck, the higher it will eventually go.
Some regulars are discussing the potential for a large acquisition of TGTX, with one person suggesting that a valuation of $18 to $22 billion is closer to fair, given the positive effect of the self-administered subcutaneous formulation on the company's TAM.

Newcomers· Aug 28

The newcomers are focused on the potential trend reversal and trend acceleration in TGTX, with some discussing the stock's breakout and volume confirmation.
They are also interested in the momentum turning positive, as indicated by the MACD bullish crossover and the bullish divergence on MACD vs price recent lows.
The price has cleared the descending trendline with increasing volume, and the 20MA slope is turning up and the 50MA is flattening, which may lead to a longer-term bias.

Generated by AI

TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. Spea

11d agoYahoo Finance

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...

12d agoYahoo Finance

TG Therapeutics Just Pulled A Bullish Move

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

13d agoInvestor's Business Daily

Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics Stock

14d agoBenzinga

TG Therapeutics at Cantor conference: briumvi gains momentum

20d agoInvesting.com

Also Discussed

Investors talking about TGTX also mention

#	Name	Attention
1	MYOV - Myovant Sciences Ltd.	——
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
4	Axsome Therapeutics IncAXSM	0.01%0
5	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
6	CKPT - Checkpoint Therapeutics, Inc.	——
7	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
8	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
9	MRTX - Mirati Therapeutics, Inc.	——
10	DAWN - Day One Biopharmaceuticals, Inc.	——

TG Therapeutics Inc.

Healthcare
Biotechnology

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.

Website

Location

3020 Carrington Mill Blvd.

Morrisville, NC, 27560

United States

Social

What share of all stock conversation is about TGTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% -0.01	0.01% 0	0.01% -0.04

Sep 29

$TGTX's subcutaneous formulation is expected to have a positive impact on its total addressable market, potentially increasing its valuation to $18-$22B.
Mike, the company's largest shareholder, has not sold any of his 14M+ shares, suggesting he believes in the company's potential for triple-digit growth.
A potential announcement, possibly related to updated guidance, trial updates, or other news, could lead to a significant price increase of 15-25% or more in a short period.

Generated by AI

Sentiment

Of the messages about TGTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.78% -2.22	91.63% -0.33	90.6% +4.02	84.93% -3.41
Bearish	2.22% new	8.37% +0.33	9.4% -4.02	15.07% +3.41

Bullish· Sep 24

$TGTX has shown resilience in the face of market fluctuations, with a strong rebound after a 4% drop and a 85% YTD gain.
The company's profitable commercial status and strides in the multi-deca billion MS market make it an attractive investment opportunity, with the potential for a violent uptick in the next 3 months.
With the potential for dual-delivery model (both at-home injection and in-clinic infusion) and a subcutaneous Phase 3 readout in late 2026-early 2027, TGTX is well-positioned for future growth and success.

Bearish· Aug 3

$TGTX's EPS miss was due to inventory build for the SubQ launch, but this may be a capitalization error, and the company's long-term story is intact.
The stock's weakness after earnings was likely due to the EPS miss, which may have been justified by the company's own accounting practices.
$TGTX's consistent EPS misses have been a concern for Wall Street, and the stock's price action has been bearish, with some traders describing it as "absolute BS" and "very bear flaggish intraday".

Generated by AI

Topics

Of the messages about TGTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	1.62%	13.71%
Announcements	100%	25%	32.19%	37.93%
Technical Analysis	0%	75%	65.79%	23.83%
Earnings	0%	0%	0%	20.87%
Controversies	0%	0%	0.4%	1.06%
Macro	0%	0%	0%	2.6%

Earnings· Aug 3

TG Therapeutics, Inc. (TGTX) reported Q2 2026 earnings with a GAAP EPS of $0.05, missing the FactSet consensus of $0.31 by $0.26.
The company beat revenue expectations with a 70.27% YoY increase to $240.34M, and raised its full-year 2026 total global revenue target to approximately $950M.
TGTX's Q2 2026 revenue growth was driven by a 64% YoY increase in BRIUMVI U.S. net product revenue to $228M, prompting the company to raise its guidance for the year.

Analysts· Aug 2

Analysts at Goldman Sachs upgraded TG Therapeutics to Neutral from Sell, with a price target of $12.
Analyst Mayank Mamtani at B.Riley Financial reiterated a Buy rating on TG Therapeutics with a price target of $32.
Analysts at HC Wainwright increased the price target for TG Therapeutics to $41.

Announcements· Mar 19

TG Therapeutics, Inc. has secured an additional $500 million in non-dilutive capital from Blue Owl Capital, expanding its share repurchase program to $300 million.
The new five-year, $750 million senior secured credit facility with Blue Owl Capital will provide financial flexibility to support opportunistic share repurchases and business development.
The company will repay its outstanding $250 million senior secured credit facility, resulting in a net raise of $500 million in non-dilutive capital, with the option to expand the facility by an additional $250 million.

Controversies· Aug 4

TG Therapeutics, Inc. (TGTX) is being investigated for securities fraud allegations by law firms Levi & Korsinsky and Berger Montague, with a lead plaintiff deadline of September 16, 2022.
A lawsuit has been filed against TG Therapeutics, alleging that the company made false and misleading statements regarding clinical trial data for its medications Ublituximab and Umbralisib.
The FDA's approval of TG's applications for these medications is unlikely due to concerns over the safety of the medications, according to the lawsuit.

Technical Analysis· Jun 10

$TGTX has formed a clean bullish engulfing flag, following a premarket long setup at $43.60.
The stock is exhibiting a textbook breakout, likely in response to new data that impressed investors.
$TGTX is showing a classic breakout pattern, indicating a potential increase in price.

Generated by AI

Community

Of the messages about TGTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	97.18%	92.81%	90.28%
Newcomers	0%	2.82%	7.19%	9.72%

Regulars· Sep 29

The price of TGTX has been stuck at $55 for the last 3 months, but some regulars believe it will break out of this range and see significant gains, with one person thinking the subq window opening in November will lead to a price increase by Christmas.
Some regulars are optimistic about TGTX's future, citing its cash flow positivity and improving margins, with one person believing the company is worth north of $100 per share and that the longer the price stays stuck, the higher it will eventually go.
Some regulars are discussing the potential for a large acquisition of TGTX, with one person suggesting that a valuation of $18 to $22 billion is closer to fair, given the positive effect of the self-administered subcutaneous formulation on the company's TAM.

Newcomers· Aug 28

The newcomers are focused on the potential trend reversal and trend acceleration in TGTX, with some discussing the stock's breakout and volume confirmation.
They are also interested in the momentum turning positive, as indicated by the MACD bullish crossover and the bullish divergence on MACD vs price recent lows.
The price has cleared the descending trendline with increasing volume, and the 20MA slope is turning up and the 50MA is flattening, which may lead to a longer-term bias.

Generated by AI

TG Therapeutics

Social

Sep 29

Bullish· Sep 24

Bearish· Aug 3

Earnings· Aug 3

Analysts· Aug 2

Announcements· Mar 19

Controversies· Aug 4

Technical Analysis· Jun 10

Regulars· Sep 29

Newcomers· Aug 28

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

TG Therapeutics Just Pulled A Bullish Move

Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics Stock

TG Therapeutics at Cantor conference: briumvi gains momentum

Also Discussed

TG Therapeutics Inc.

Company Information

Location

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

TG Therapeutics Just Pulled A Bullish Move

Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics Stock

TG Therapeutics at Cantor conference: briumvi gains momentum

Also Discussed

Social

Sep 29

Bullish· Sep 24

Bearish· Aug 3

Earnings· Aug 3

Analysts· Aug 2

Announcements· Mar 19

Controversies· Aug 4

Technical Analysis· Jun 10

Regulars· Sep 29

Newcomers· Aug 28